Last updated: 2026-09-16 11:44:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
NeOnc Technologies Holdings, Inc. (NTHI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.60, with a market capitalisation of $108.88M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.01 to $12.99. This page covers its latest market performance, valuation, price trends and company information.
$108.88M | |
$3.38 | |
$25.00 | |
$3.01 | |
$3.31 | |
2.00 | |
170.19K | |
-- | |
$12.99 | |
$3.01 | |
-- | |
-- |
NeOnc Technologies Holdings, Inc. (NTHI) is trading at $3.60 in pre-market trading as of 2026-09-16 11:37:00, up 8.73% ($0.29) from the previous close of $3.31
Pre-market trading shows how investors are pricing NTHI before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, NeOnc Technologies Holdings, Inc. (NTHI) moved from $5.03 to $3.60, representing a decline of 28.45% ($1.43).
The stock traded between $3.20 and $5.20 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 245.16 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5.9%
NTHI is currently trading at $3.60, placing it 5.9% of the way from its 52-week low of $3.01 to its 52-week high of $12.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NeOnc Technologies Holdings, Inc. (NTHI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.